Biblio

Author Title [ Type

] Year

Filters: Author is Szer, Jeff [Clear All Filters]

Journal Article

Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBc, Kröger N, Mohty M, Galeano S, Okamoto S, et al. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.

Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, et al. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica. 2024.

McQuilten Z, Heritier S, Fox L, Fox V, Young L, Blombery P, Cunningham I, Curnow J, Higgins A, Hiwase DK, et al. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials. BMJ Open. 2024;14(1):e076246.

Tew M, Douglas AP, Szer J, Bajel A, Harrison SJ, Tio SYen, Worth LJ, Hicks RJ, Ritchie D, Slavin MA, et al. Evaluating the cost-effectiveness of [F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients. Cancer Imaging. 2023;23(1):119.

Douglas A, Thursky K, Spelman T, Szer J, Bajel A, Harrison S, Tio SYen, Bupha-Intr O, Tew M, Worth L, et al. [F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Haematol. 2022.

Yoshimi A, Baldomero H, Horowitz M, Szer J, Niederwieser D, Gratwohl A, Kodera Y. Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. JAMA. 2016;315(2):198-200.

de Latour RPeffault, Griffin M, Kelly RJ, Szer J, de Castro C, Horneff R, Tan L, Yeh MM, Panse JPeter. Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2024.

McErlean G, Bajel A, Bhattacharyya A, Brown N, Lourenco RDe Abreu, Greenwood M, Kerridge I, Kim N, Kliman D, Maneze D, et al. If we do not count it, it does not count: ethnicity in allogeneic haemopoietic stem cell transplant in Australia. Intern Med J. 2023.

Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transplant. 2020.

Terriou L, Lee JWook, Forsyth C, Griffin M, Szer J, Röth A, Gustovic P, Metzger J, Patel AS, Patriquin CJ. Long-term effectiveness of eculizumab: Data from the International PNH Registry. Eur J Haematol. 2023.

Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian J-J, de Castro C, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021;384(11):1028-1037.

de Latour RPeffault, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian J-J, de Castro CM, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9(9):e648-e659.

Douglas AP, Yu L, Sundararajan V, Szer J, Ritchie D, Slavin MA, Sasadeusz J, Visvanathan K. The QuantiFERON Monitor Assay is predictive of infection post allogeneic hematopoietic cell transplant. Transpl Infect Dis. 2020:e13260.

Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.

Curran D, Matthews S, Rowley SD, Young J-AH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PHaran, Dickinson M, Idrissi MEl, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019.

Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020.

Szer J, Elmoazzen H, Fechter M, Hwang W, Korhonen M, Miller J, Mengling T, Shaw B, Stein J. Safety of Living Donation of Hematopoietic Stem Cells. Transplantation. 2016.

Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, et al. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. Lancet Haematol. 2022;9(8):e605-e614.

Szer J. Is there no place like home for an allogeneic stem cell transplant?. Bone Marrow Transplant. 2020.

Lim ABM, Roberts AW, Mason K, Bajel A, Szer J, Ritchie DS. Validating the Allogeneic Stem Cell Transplantation Disease Risk Index: Sample Size, Follow-up, and Local Data Are Important. Transplantation. 2014.

Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, et al. WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplant Cell Ther. 2022.